Business Context and Reporting Period
This Form 8-K is a current report filed by Graybug Vision, Inc. (not Calcimedica, Inc., as indicated in the metadata) on February 28, 2023, with supplemental disclosures dated March 3, 2023. The filing addresses the termination of a senior officer and provides supplemental information regarding the proposed merger between Graybug and CalciMedica, Inc. The merger agreement, originally dated November 21, 2022, was amended on February 10, 2023, and involves Merger Sub merging with CalciMedica, which will continue as a wholly owned subsidiary of Graybug.
Key Financial Metrics and Projections
The filing does not report historical revenue, profit, or cash flow for the current period. Instead, it provides unaudited financial projections for the combined entity and specific valuation data used in the merger analysis:
- Graybug Cash Position: As of September 30, 2022, Graybug held approximately $43.6 million in net cash. Estimated net cash at the consummation of the merger is approximately $26.5 million.
- CalciMedica Cash Position: Net cash of approximately $11.5 million.
- Valuation: Piper Sandler calculated an implied intrinsic value for Graybug of $1.06 per share based on closing cash and diluted shares.
- Projected Revenue (Combined Entity): Projections show $0 revenue for FY 2023 through FY 2026. Revenue is projected to begin in FY 2027 at $1 million, growing to $668 million by FY 2038.
- Projected EBITDA: Negative EBITDA is projected through FY 2026 (ranging from $(19) million to $(64) million). Positive EBITDA is projected to begin in FY 2027 ($12 million), reaching $555 million by FY 2038.
- Severance Costs: Graybug agreed to pay former Chief Medical Officer Parisa Zamiri approximately $829,084 in cash severance, plus COBRA premiums and 100% acceleration of stock awards.
Material Changes and Events
The filing details several material events and corrections to previously disclosed information:
- Executive Departure: Parisa Zamiri was terminated as Chief Medical Officer on February 28, 2023, in advance of the merger closing. She will transition to a consulting role at $350/hour for up to 8 hours/week until May 21, 2023.
- Correction of Share Data: Piper Sandler corrected diluted share information for CalciMedica used in financial analyses. The corrected ranges for diluted shares outstanding are 146–174 million (public companies analysis), 158–167 million (IPO analysis), and 159–172 million (DCF analysis). This correction did not change the fairness opinion or implied ownership percentages for Graybug stockholders.
- Advisory Fees: Piper Sandler will receive a total fee of $3,000,000 contingent on the merger closing, with $850,000 already earned (retainer and opinion fees).
Guidance, Risks, and Contingencies
Legal Proceedings: Four lawsuits (collectively "Stockholder Litigation") have been filed in federal courts against Graybug and its directors. Plaintiffs allege the proxy statement misrepresents or omits material information regarding the merger, specifically concerning financial projections and advisor analyses. Plaintiffs seek injunctions to stop the merger, rescission, and damages. Additionally, nine stockholders have sent demand letters requesting corrective disclosures. Graybug believes these claims are without merit but notes no assurance of prevailing.
Merger Conditions: The merger is subject to the satisfaction or waiver of conditions set forth in the Merger Agreement. The supplemental disclosure was issued to address the litigation and demand letters to avoid disruption to the merger.
Financial Projections: The projections reflect assumptions regarding the probability of success, including regulatory approvals and commercialization. The filing explicitly states that the analysis did not account for any assumed additional cash needs of CalciMedica to fund its business plan.
Investor Verification Checklist
- Verify the status of the four pending lawsuits (Bushansky, Connelly, Plumley, and Franchi) and any potential impact on the merger timeline.
- Confirm the final exchange ratio and ownership percentage for Graybug stockholders in the combined company following the corrected share count analysis.
- Review the definitive proxy statement for the full details of the merger agreement and the specific conditions required for closing.
- Assess the validity of the long-term revenue projections (starting FY 2027) given the current lack of commercial revenue and the reliance on regulatory approvals.
- Monitor the cash burn rate of Graybug to ensure the estimated $26.5 million closing cash is sufficient to fund operations until projected revenue generation.